-
Mashup Score: 0HARMONi-2 Interim Analysis: Ivonescimab Shows PFS Improvements Over Pembrolizumab in NSCLC - 2 day(s) ago
Ivonescimab showed significant improvements in progression-free survival compared with pembrolizumab in previously untreated advanced PD-L1–positive non-small cell lung cancer.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0How Socioeconomic Factors Impact Surgical Care for US Veterans With Early-Stage NSCLC | Docwire News - 24 day(s) ago
Though veterans with high socioeconomic deprivation experience less than optimal surgical care, they do not experience inferior long-term outcomes after surgery for NSCLC.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 How do socioeconomic factors affect care and surgical outcomes for veterans with NSCLC? 📰 A new study by a team from @WUSTL provided insights and key action items. ➡️ Learn more: https://t.co/DToVHr1vQZ #lcsm #LungCancer #NSCLC https://t.co/1Xzs3rWi5X
-
-
Mashup Score: 1Phase 3 INTerpath-009 Trial of mRNA-4157 Plus Pembrolizumab for NSCLC Begins Recruitment | Docwire News - 2 month(s) ago
The pivotal phase 3 INTerpath-009 trial has begun global recruitment of patients with resectable non-small cell lung cancer, according to Merck and Moderna.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Recruitment is underway for the phase 3 INTerpath-009 trial of V940 (mRNA-4157) plus pembrolizumab for NSCLC, according to an announcement from Moderna and Merck. ➡️ Learn more: https://t.co/OIEaHQ3Y2E #lcsm #LungCancer #NSCLC https://t.co/1Z94cX8hV0
-
-
Mashup Score: 0Study Highlights Importance of Pretreatment Frailty Assessments for Older Adults With Advanced NSCLC | Docwire News - 2 month(s) ago
Integrating pretreatment frailty assessments into clinical workflows may help oncologists better identify older adults with NSCLC at risk for poor outcomes.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📋 Can pretreatment frailty assessments help identify older adults with NSCLC who are at risk for poor outcomes? 💡A study published in @OncJournal by a team from @UCSF provided insights. ➡️ Learn more: https://t.co/2mBUJwokeb #lcsm #LungCancer #NSCLC https://t.co/Y6CpVhFT8F
-
-
Mashup Score: 1How Socioeconomic Factors Impact Surgical Care for US Veterans With Early-Stage NSCLC | Docwire News - 2 month(s) ago
Though veterans with high socioeconomic deprivation experience less than optimal surgical care, they do not experience inferior long-term outcomes after surgery for NSCLC.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 How do socioeconomic factors affect care and surgical outcomes for veterans with NSCLC? 📰 A new study by a team from @WUSTL provided insights and key action items. ➡️ Learn more: https://t.co/yULaGnbLvZ #lcsm #LungCancer #NSCLC https://t.co/4PAh7ITbOL
-
-
Mashup Score: 1Phase 3 INTerpath-009 Trial of mRNA-4157 Plus Pembrolizumab for NSCLC Begins Recruitment | Docwire News - 2 month(s) ago
The pivotal phase 3 INTerpath-009 trial has begun global recruitment of patients with resectable non-small cell lung cancer, according to Merck and Moderna.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Recruitment is underway for the phase 3 INTerpath-009 trial of V940 (mRNA-4157) plus pembrolizumab for NSCLC, according to an announcement from Moderna and Merck. ➡️ Learn more: https://t.co/OIEaHQ3Y2E #lcsm #LungCancer #NSCLC https://t.co/1Z94cX8hV0
-
-
Mashup Score: 1How Socioeconomic Factors Impact Surgical Care for US Veterans With Early-Stage NSCLC | Docwire News - 3 month(s) ago
Though veterans with high socioeconomic deprivation experience less than optimal surgical care, they do not experience inferior long-term outcomes after surgery for NSCLC.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 How do socioeconomic factors affect care and surgical outcomes for veterans with NSCLC? 📰 A new study by a team from @WUSTL provided insights and key action items. ➡️ Learn more: https://t.co/yULaGnbLvZ #lcsm #LungCancer #NSCLC https://t.co/4PAh7ITbOL
-
-
Mashup Score: 1Phase 3 INTerpath-009 Trial of mRNA-4157 Plus Pembrolizumab for NSCLC Begins Recruitment | Docwire News - 3 month(s) ago
The pivotal phase 3 INTerpath-009 trial has begun global recruitment of patients with resectable non-small cell lung cancer, according to Merck and Moderna.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Recruitment is underway for the phase 3 INTerpath-009 trial of V940 (mRNA-4157) plus pembrolizumab for NSCLC, according to an announcement from Moderna and Merck. ➡️ Learn more: https://t.co/OIEaHQ3Y2E #lcsm #LungCancer #NSCLC https://t.co/1Z94cX8hV0
-
🫁 Ivonescimab significantly improved PFS compared with pembrolizumab in patients with previously untreated advanced PD-L1–positive NSCLC, according to HARMONi-2 results published today in @TheLancet. ➡️ Learn more: https://t.co/j2Pe58DSfu #lcsm #LungCancer #NSCLC https://t.co/hnPcKHPpSr